Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 451 across all filing types
Latest filing 2021-08-17 Regulatory Filings
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings
2021-08-17 English
Updates
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed report of voting results and the scrutinizer's report for the 28th Annual General Meeting (AGM) of Orchid Pharma Limited held on August 13, 2021. It includes voting outcomes on various resolutions passed during the AGM, references to the Companies Act, SEBI regulations, and the process of remote e-voting and e-voting at the AGM. The content is focused on the disclosure of voting results and the official report of the scrutinizer, not the AGM presentation materials or the annual report itself. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is substantial and contains detailed voting data, confirming it is not a mere announcement or a proxy solicitation. Therefore, the correct classification is DVA with high confidence.
2021-08-15 English
Updates
Regulatory Filings
2021-08-14 English
Financial Result Updates
Regulatory Filings
2021-08-13 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a communication from Orchid Pharma Limited dated August 13, 2021, addressed to stock exchanges (NSE and BSE) regarding the outcome of a Board meeting held on the same date. It announces the approval of unaudited standalone and consolidated financial results for the quarter ended June 30, 2021, along with the Limited Review Reports from statutory auditors. The document includes detailed financial data for the quarter, such as income, expenses, and losses, indicating substantive financial information is presented. The reference to Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, which mandates quarterly financial disclosures, further supports this classification. The document is not merely an announcement of a report's publication but contains the actual financial results and auditor's review. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2021-08-13 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document text is extremely short (703 characters) and consists mainly of listing department addresses and stock exchange information for National Stock Exchange of India Ltd, BSE Limited, Luxembourg Stock Exchange, and London Stock Exchange. There is no substantive financial data, report content, or detailed information about company activities, financial results, or management. The document appears to be a brief announcement or notice related to stock exchange listings rather than a full report or detailed filing. Given the brevity and nature of the content, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-08-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.